0 3 HIV HIV NNP 4 8 type type NN 9 10 1 1 CD 11 19 protease protease NN 20 30 activation activation NN 31 33 of of IN 34 42 NF-kappa NF-kappa NNP 43 44 B B NNP 45 51 within within IN 52 53 T t NN 54 62 lymphoid lymphoid JJ 63 68 cells cell NNS 68 69 . . . 71 79 NF-kappa NF-kappa NNP 80 81 B B NNP 82 84 is be VBZ 85 86 a a DT 87 94 nuclear nuclear JJ 95 102 protein protein NN 103 105 of of IN 106 109 the the DT 110 113 rel rel NN 114 122 oncogene oncogene NN 123 129 family family NN 130 137 capable capable JJ 138 140 of of IN 141 150 enhancing enhance VBG 151 164 transcription transcription NN 165 167 of of IN 168 175 several several JJ 176 184 cellular cellular JJ 185 190 genes gene NNS 190 191 , , , 192 201 including include VBG 202 206 IL-2 il-2 NN 207 210 and and CC 211 214 the the DT 215 219 IL-2 il-2 NN 220 228 receptor receptor NN 228 229 , , , 230 233 and and CC 234 239 viral viral JJ 240 245 genes gene NNS 246 257 transcribed transcribe VBN 258 262 from from IN 263 266 the the DT 267 272 HIV-1 HIV-1 NNP 273 276 LTR LTR NNP 276 277 . . . 278 280 It it PRP 281 284 has have VBZ 285 289 been be VBN 290 298 reported report VBN 299 303 that that IN 304 309 HIV-1 HIV-1 NNP 310 318 protease protease NN 319 322 may may MD 323 329 cleave cleave VB 330 333 the the DT 334 342 NF-kappa NF-kappa NNP 343 344 B B NNP 345 354 precursor precursor NN 355 357 to to TO 358 361 its its PRP$ 362 368 active active JJ 369 373 form form NN 374 376 in in FW 377 382 vitro vitro FW 382 383 . . . 384 386 In in IN 387 391 this this DT 392 397 study study NN 398 401 the the DT 402 409 effects effect NNS 410 412 of of IN 413 416 HIV HIV NNP 417 425 protease protease NN 426 428 on on IN 429 437 NF-kappa NF-kappa NNP 438 439 B B NNP 440 449 precursor precursor NN 450 460 activation activation NN 461 465 were be VBD 466 474 examined examine VBN 475 477 in in IN 478 484 Jurkat Jurkat NNP 485 486 T t NN 487 492 cells cell NNS 493 495 by by IN 496 507 introducing introduce VBG 508 509 a a DT 510 518 protease protease NN 519 529 expression expression NN 530 536 vector vector NN 537 541 into into IN 542 545 the the DT 546 551 cells cell NNS 551 552 . . . 553 562 Increased increase VBN 563 571 NF-kappa NF-kappa NNP 572 573 B B NNP 574 582 activity activity NN 583 586 was be VBD 587 595 observed observe VBN 596 599 and and CC 600 604 this this DT 605 614 increased increase VBN 615 623 activity activity NN 624 627 was be VBD 628 635 blocked block VBN 636 638 by by IN 639 640 a a DT 641 649 specific specific JJ 650 659 inhibitor inhibitor NN 660 662 of of IN 663 666 the the DT 667 672 viral viral JJ 673 681 protease protease NN 681 682 . . . 683 688 Viral viral JJ 689 702 transcription transcription NN 702 703 , , , 704 706 as as IN 707 715 measured measure VBN 716 721 using use VBG 722 729 LTR-CAT LTR-CAT NNP 730 736 assays assay NNS 736 737 , , , 738 741 was be VBD 742 746 only only RB 747 755 slightly slightly RB 756 764 enhanced enhance VBN 765 767 in in IN 768 771 the the DT 772 784 HIV-protease hiv-protease NN 785 795 expressing express VBG 796 801 cells cell NNS 801 802 , , , 803 808 while while IN 809 818 secretion secretion NN 819 821 of of IN 822 826 IL-2 il-2 NN 827 830 and and CC 831 841 expression expression NN 842 844 of of IN 845 848 the the DT 849 853 IL-2 il-2 NN 854 862 receptor receptor NN 863 867 were be VBD 868 871 not not RB 872 880 affected affect VBN 880 881 . . . 882 885 The the DT 886 893 limited limited JJ 894 904 activation activation NN 905 907 of of IN 908 916 NF-kappa NF-kappa NNP 917 918 B B NNP 919 921 by by IN 922 925 HIV HIV NNP 926 934 protease protease NN 935 942 appears appear VBZ 943 951 unlikely unlikely JJ 952 954 to to TO 955 959 have have VB 960 961 a a DT 962 973 significant significant JJ 974 980 effect effect NN 981 983 on on IN 984 989 virus virus NN 990 1000 expression expression NN 1001 1003 or or CC 1004 1005 T t NN 1006 1010 cell cell NN 1011 1019 function function NN 1019 1020 . . .